Ubs Oconnor LLC 89bio, Inc. Transaction History

Ubs Oconnor LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $350,508 - $593,666	-43,113 Reduced 54.52%	35,962 $418,000
Q4 2023 Feb 14, 2024	SELL	$6.66 - $16.03 $131,621 - $316,800	-19,763 Reduced 20.0%	79,075 $883,000
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $225,900 - $291,150	15,000 Added 17.89%	98,838 $1.53 Million
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $1.19 Million - $1.85 Million	83,838 New	83,838 $1.59 Billion
Q1 2023 May 15, 2023	SELL	$10.48 - $16.94 $559,118 - $903,765	-53,351 Reduced 48.82%	55,939 $851,000
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $95,253 - $219,668	17,256 Added 18.75%	109,290 $0
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $277,942 - $644,238	92,034 New	92,034 $533 Million

164

110M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $508M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.